Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-30,000
Closed -$764K 1182
2025
Q3
$764K Hold
30,000
0.03% 406
2025
Q2
$727K Hold
30,000
0.03% 430
2025
Q1
$760K Buy
+30,000
New +$785K 0.04% 347
2024
Q4
Sell
-20,000
Closed -$579K 1048
2024
Q3
$579K Sell
20,000
-10,000
-33% -$292K 0.03% 452
2024
Q2
$839K Hold
30,000
0.04% 329
2024
Q1
$833K Buy
+30,000
New +$832K 0.05% 313
2023
Q3
Sell
-10,100
Closed -$370K 900
2023
Q2
$370K Buy
+10,100
New +$393K 0.02% 493
2021
Q4
Sell
-25,000
Closed -$1.07M 1303
2021
Q3
$1.07M Buy
+25,000
New +$1.11M 0.05% 393
2020
Q4
Sell
-48,800
Closed -$1.7M 918
2020
Q3
$1.7M Sell
48,800
-62,292
-56% -$2.18M 0.08% 201
2020
Q2
$3.45M Buy
+111,092
New +$3.77M 0.2% 117

Other funds holding PFE

CSS LLC's PFE Position: Q1 2026 in Review

CSS LLC reduced its Pfizer (PFE) stake by 12% in Q1 2026, selling an estimated $134K and leaving 37,121 shares worth $1.04M. The position accounts for 0.05% of the portfolio, ranked #321.

CSS LLC first reported a position in PFE in Q4 2013 and has held it in 27 quarters since. The position peaked at $1.67M in Q2 2020. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • CSS LLC held 37,121 shares of Pfizer worth $1.04M as of Q1 2026.
  • CSS LLC sold 5,050 Pfizer shares in Q1 2026, an estimated $134K.
  • Pfizer made up 0.05% of CSS LLC's portfolio in Q1 2026, its #321 holding.
  • CSS LLC first reported a position in Pfizer in Q4 2013 and has held it in 27 quarters since.
  • CSS LLC's Pfizer position peaked at $1.67M in Q2 2020.
  • 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on CSS LLC's 13F filing for Q1 2026, filed 15 May 2026.